Related Experiment Video
Updated: Jun 15, 2026
12:43
A Protocol for Comprehensive Assessment of Bulbar Dysfunction in Amyotrophic Lateral Sclerosis (ALS)
Published on: February 21, 2011
Dysarthria in amyotrophic lateral sclerosis: A review
Barbara Tomik1, Roberto J Guiloff
1Department of Neurology, Jagiellonian University, Krakow, Poland. tomik@neuro.cm-uj.krakow.pl <tomik@neuro.cm-uj.krakow.pl>
Summary
Dysarthria, a speech disorder in amyotrophic lateral sclerosis (ALS), impacts articulation and intelligibility. Optimizing communication is key to maintaining quality of life for ALS patients.
Area of Science:
- Neurology
- Speech-Language Pathology
Background:
- Dysarthria significantly affects speech articulation and intelligibility in patients with amyotrophic lateral sclerosis (ALS).
- Communication loss in ALS can lead to social isolation and reduced quality of life.
- Current knowledge on dysarthria in ALS is fragmented across various medical disciplines.
Purpose of the Study:
- To consolidate and review the current understanding of dysarthria in ALS.
- To highlight the importance of effective communication management for ALS patients.
- To identify gaps in research and suggest future directions for managing dysarthria in ALS.
Main Methods:
- Comprehensive literature review synthesizing information from physiological, pathological, speech therapy, otorhinolaryngological, and neurological publications.
- Analysis of clinical features, differential diagnosis, pathophysiology, investigations, and management strategies for dysarthria in ALS.
Main Results:
- Dysarthria in ALS presents with varied abnormalities in articulation, intelligibility, phonation, and facial movement rate.
- Effective management aims to preserve communication abilities for as long as possible.
- There is a need for standardized assessment methods and controlled trials for therapeutic strategies.
Conclusions:
- A unified understanding of dysarthria in ALS is crucial for patient care.
- Further research is required to compare assessment tools and validate therapeutic interventions.
- Optimizing communication is essential for enhancing the quality of life for individuals with ALS.
Related Concept Videos
01:15Parkinson's Disease: Overview
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
01:26Cross-bridge Cycle
As muscle contracts, the overlap between the thin and thick filaments increases, decreasing the length of the sarcomere—the contractile unit of the muscle—using energy in the form of ATP. At the molecular level, this is a cyclic, multistep process that involves binding and hydrolysis of ATP, and movement of actin by myosin.
01:12Alterations in Muscle Tone ll
Alterations in muscle tone are common manifestations of neurological disorders and reflect dysfunction within different nervous system regions. Spasticity, paratonia, and dystonia represent distinct forms of hypertonia, each with unique mechanisms, clinical features, and diagnostic importance.CharacteristicsSpasticity happens from upper motor neuron lesions and is characterized by velocity-dependent resistance to passive movement. Clinical features include:Exaggerated deep tendon reflexesClonus...
01:24Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
01:20Myasthenia Gravis: Overview and Treatment
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
01:22Myasthenia Gravis ll: Pathophysiology
The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...